Medical Marketing in the United States, 1997-2016

Area of Science:

• Health economics
• Medical marketing
• Pharmaceutical industry regulation

Background:

• Healthcare companies utilize extensive promotional activities to boost sales and market share.
• These activities influence public and professional perceptions of treatments, diagnostics, and disease definitions.

Purpose of the Study:

• To analyze trends in prescription drug, disease awareness, health service, and laboratory test marketing in the U.S. from 1997-2016.
• To examine the consequences and regulatory landscape of these marketing practices over two decades.

Main Methods:

• Analysis of consumer and professional marketing expenditures and ad volumes using data from Kantar Media and IQVIA.
• Review of regulatory actions by the FDA, FTC, and DOJ, alongside literature searches of medical, business, and news databases.

Main Results:

• Total medical marketing spending increased from $17.7 to $29.9 billion (2016 dollars) between 1997 and 2016.
• Direct-to-consumer (DTC) advertising saw the most rapid growth, increasing from $2.1 to $9.6 billion, with a notable rise in prescription drug and health service ads.
• Pharmaceutical marketing to professionals remained substantial, despite increased regulatory scrutiny and over $11 billion in fines for deceptive practices.

Conclusions:

• Medical marketing, especially DTC advertising, has grown substantially over 20 years.
• Pharmaceutical marketing to healthcare professionals continues to dominate spending, even with policies aimed at reducing industry influence.
• Regulatory oversight has not kept pace with the expansion of medical marketing activities.